Open menu
Posted: July 7, 2010

Nanomedicine Company SoluBest Appoints New CEO

(Nanowerk News) SoluBest, a company developing an easy-to-integrate technological platform for solving the problem of drug insolubility, has appointed Dr. Amir Zalcenstein as new CEO.
Dr. Zalcenstein joined SoluBest in 2007 as Business Development Manager and was appointed to Senior Director of Business Development in 2008. Prior to joining SoluBest he worked with Ernst & Young's GIA division as a senior consultant. He holds an MBA of Technion (Haifa, Israel) and a doctoral degree in cancer genetics from the Weizmann Institute of Science (Rehovot, Israel). His post-doctorate dealt with nanotechnology.
"I am very happy to take over as CEO," said Amir Zalcenstein, "as SoluBest's technology is meeting an increasing demand by global pharmaceutical companies who need to solve the problem that over 40% of the drugs on the market and up to 60% of drugs currently in development are insoluble."
"These are exciting times for SoluBest," said Dr. Ronnie Hershman, Chairman of the Board of SoluBest. "We have never been closer to achieving our business goals: Amir has been effective with our business development over the last three years, and was instrumental in launching SoluBest's very successful ,free formulation initiative.' With his vision and leadership, we feel he is the right person at the right time to advance the company to significant revenue generation and further business opportunities. I fully expect Solubest to enter a period of profitability and growth under his leadership. We support him fully and wish him much success."
SoluBest's "free formulation initiative" offers interested parties to formulate up to 5 molecules for free, with no obligation and no cost except the cost of the API. Already, the initiative led to various collaboration agreements, among them top 10 global pharmaceutical and agrochemical companies and to marketing agreements with leading CROs from the UK an the US.
About SoluBest
SoluBest is a clinical stage developer of enabling drug delivery technologies, established in 2001 with the intention of developing smart polymer, self-assembling nano-particle constructs. The company is located at the Weizmann Science Park in Ness Ziona, Israel, and employs a team of experienced polymer and analytical chemists.
SoluBest is currently completing a series D financing round, raising $1.5M, of which $1.3M have been raised already.
About SoluBest's Solumer™ Technology
SoluBest's proprietary Solumer™ process addresses the issue of drug insolubility by creating therapeutic and nutraceutical formulations in which active drug molecules are uniquely interwoven with FDA-approved polymers. Once in the body, these oral, solid-dosage formulations disintegrate into stable nano-particles, potentially increasing drug solubility and oral absorption, thus improving the bio-performance of insoluble drugs and nutritional actives.
SoluBest's technology is designed to provide significant advantages, among others:
  • Improved solubility of a broad range of small molecules,
  • Freedom to operate per product,
  • Superior bio-availability as demonstrated in two exploratory clinical trials,
  • Ease of production, using existing equipment with little or no modification,
  • Quick turnaround through rapid feasibility and scale-up time,
  • Low regulatory risk by using safe and FDA-approved polymer excipients and environmentally safe solvents.
  • Source: SoluBest (press release)
    Subscribe to a free copy of one of our daily
    Nanowerk Newsletter Email Digests
    with a compilation of all of the day's news.
    These articles might interest you as well: